Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

EP: 1.Assessing HER2 Status Across Tumor Types

EP: 2.ADCs Targeting HER2+ Breast Cancer

EP: 3.ADCs Targeting HER2+ Gynecologic Cancers

Now Viewing

EP: 4.Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

EP: 5.ADCs Targeting GI Cancers

EP: 6.ADCs Targeting HER2+ Lung Cancer

EP: 7.Impact of ADCs on Brain Metastases

EP: 8.ADCs Targeting HER2+ GU Cancers

EP: 9.Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

EP: 10.The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

EP: 11.Managing ILD and Pneumonitis Risk From ADCs

EP: 12.Managing Toxicities in Short- and Long-Term Treatment with ADCs

EP: 13.Managing Hematologic AEs Associated with ADC Treatments

EP: 14.Management of Emetogenicity of Antibody-Drug Conjugates

EP: 15.ADC Sequencing

EP: 16.Emerging ADCs in Development

EP: 17.Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

EP: 18.The Future for HER2-Directed ADCs

EP: 19.Key Takeaways and Closing Thoughts on ADCs

Video content above is prompted by the following:

• Can you please offer an overview of the primary results from the DESTINY-PanTumor02 trial (Meric-Bernstam_J Clin Oncol_2024), specifically in regard to each of the following:
  • cervical
  • ovarian cancers
  • endometrial
    • STATICE trial results (Nishikawa J Clin Oncol 2023)
    • What is the potential for DB-1303 in endometrial cancer (Moore_J Clin Oncol_2023)
• Where in the treatment sequencing do you expect HER2-direct ADCs to fit?